Product Approval Information - New Drug Application
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
February 19, 2002
Our Reference: OB-NDA 19-862/006
Medi-Physics, Incorporated d.b.a. Amersham Health
Attention: David Risley
Director, Regulatory Affairs
101 Carnegie Center
Princeton, NJ 08540
Dear Mr. Risley:
We acknowledge receipt of your supplemental drug application
submitted under section 505(b) of the Federal Food, Drug, and
Cosmetic Act for the following:
Indiclor (Indium In-111 Chloride-Sterile Solution)
NDA Number: 19-862
Supplement Number: 6
Date of Supplement: November 13, 2001
Date of Receipt: November 26, 2001
This prior approval supplemental application proposes the
following changes: to provide for use in radiolabeling Ibritumomab
Tiuxetan (Zevalin) and to remove use in radiolabeling Imciromab
Pentetate (Myoscint).
We have completed the review of this supplement and it is
approved effective this date.
Please submit all final printed labeling at the time of use and
include implementation information on FDA Form 2567. Please provide
a PDF-format electronic copy as well as original paper copies (ten
for circulars and five for other labels).
We remind you that you must comply with the requirements of an
approved NDA set forth under 21 CFR 314.80 and 314.81, including
submission of annual reports.
If you have any questions, contact Mr. Michael Noska, Regulatory
Project Manager, at (301) 827-5101.
Sincerely yours,
--- signature ---
Karen D. Weiss, M.D.
Director
Division of Clinical Trial Design and Analysis
Office of Therapeutics Research and Review
Center for Biologics Evaluation and Research
Last Updated: 4/29/2002
 Back
to Top 
Back to Index
Date created: September 26, 2003
 |
